2010305A19Rik Inhibitors
Chemical inhibitors of 2010305A19Rik can impact its function through various mechanisms, each specific to the inhibitor's target within cellular signaling pathways. Staurosporine, for instance, can non-selectively inhibit a wide range of protein kinases, which are enzymes that catalyze the transfer of a phosphate group to a protein in a process called phosphorylation. Since phosphorylation states can alter a protein's function, the inhibition by staurosporine can lead to a decrease in the phosphorylation state of 2010305A19Rik if it is a protein whose activity is regulated by phosphorylation. Similarly, both LY294002 and wortmannin target PI3K, a lipid kinase that plays a critical role in the regulation of cell growth, proliferation, and survival through its product PIP3. By inhibiting PI3K, these inhibitors can prevent the activation or function of proteins like 2010305A19Rik that may operate downstream of PI3K signaling.
Inhibition of the MEK/ERK pathway by PD98059 and U0126 can result in decreased activation of downstream proteins, including 2010305A19Rik. PD98059 inhibits MEK, which is an upstream activator of ERK, while U0126 is a more selective inhibitor of both MEK1 and MEK2, leading to reduced ERK phosphorylation and activity. SP600125's inhibition of JNK, another MAPK pathway component, can lead to reduced activity of 2010305A19Rik if it is a downstream target of JNK. SB203580 specifically inhibits p38 MAP kinase, and if 2010305A19Rik's function is influenced by p38 MAPK, then the inhibition by SB203580 can result in decreased function of 2010305A19Rik. PP2, as an inhibitor of Src family tyrosine kinases, can prevent the phosphorylation and subsequent activation of 2010305A19Rik if it relies on Src kinase activity. AG490, which specifically inhibits JAK2, can reduce the activity of 2010305A19Rik by attenuating the JAK/STAT signaling pathway that may be involved in its regulation. PD173074 targets the FGFR and can inhibit downstream signaling pathways that potentially include the activation of 2010305A19Rik. Lastly, Bisindolylmaleimide I, as a selective PKC inhibitor, can affect the activation state of 2010305A19Rik if PKC isoforms regulate it.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine non-selectively inhibits protein kinases by binding to the ATP binding site. In the context of 2010305A19Rik, this inhibition could reduce the phosphorylation state of the protein if 2010305A19Rik is a phosphorylation-dependent protein. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a specific inhibitor of phosphoinositide 3-kinases (PI3K). If 2010305A19Rik functions downstream of PI3K or its product PIP3, wortmannin's inhibition of PI3K could prevent the activation or function of 2010305A19Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, similar to wortmannin. It competitively inhibits ATP binding to the catalytic site of PI3K, potentially leading to a decrease in downstream signaling pathways that would otherwise contribute to the functional state of 2010305A19Rik. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR) complex 1 (mTORC1). If 2010305A19Rik is involved in pathways regulated by mTORC1, rapamycin's inhibition of mTORC1 could inhibit the functional activation of 2010305A19Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK, which is upstream of ERK in the MAPK/ERK pathway. By preventing ERK's activation, PD98059 could inhibit downstream proteins that are activated by ERK, including 2010305A19Rik if it is part of this signaling cascade. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of both MEK1 and MEK2. Inhibition of these MEK enzymes would lead to decreased ERK phosphorylation and activity. If 2010305A19Rik's function is dependent on the MEK/ERK pathway, U0126's inhibition of MEK could lead to functional inhibition of 2010305A19Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), which is part of the MAPK signaling pathway. Inhibition of JNK activity by SP600125 would result in the inhibition of downstream targets regulated by JNK phosphorylation. If 2010305A19Rik is regulated by JNK, its activity would be inhibited by SP600125. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAP kinase. If 2010305A19Rik is a substrate of p38 MAPK or functions downstream of this kinase, SB203580's inhibition of p38 MAPK activity could lead to reduced phosphorylation and inhibition of 2010305A19Rik. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. If 2010305A19Rik's activity relies on phosphorylation by Src kinases, PP2 would inhibit its function by preventing this phosphorylation. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG490 is a tyrosine kinase inhibitor that specifically inhibits JAK2. If 2010305A19Rik is activated by JAK/STAT signaling, inhibition of JAK2 by AG490 would lead to decreased activation of STATs and subsequent inhibition of 2010305A19Rik if it is a downstream target. | ||||||